Concepedia

James F. Blake

JF

Statistics

Publications

54

Citations

5.8K

H-Index

36

Active since

1987

Affiliations

Array BioPharma (United States)(Current)

Pfizer (United States)

Roche (United States)

Mirati Therapeutics (United States)

Loxo Oncology at Lilly (United States)

James F. Blake is an author at Array BioPharma (United States) specializing in pharmacology, medicinal chemistry, and chemistry.

Publications per year

1987–2021

54

Publications

54

Identification of MRTX1133, a Noncovalent, Potent, and Selective KRAS <sup>G12D</sup> Inhibitor

Xiaolun Wang, Shelley Allen, James F. Blake et al. · Journal of Medicinal Chemistry · 2021 · 708 citations · Full text

Medicine, Medicinal Chemistry, Oncology +14

Identification of the Clinical Development Candidate <b>MRTX849</b>, a Covalent KRAS<sup>G12C</sup> Inhibitor for the Treatment of Cancer

Jay B. Fell, John P. Fischer, Brian R. Baer et al. · Journal of Medicinal Chemistry · 2020 · 594 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +17

A Next-Generation TRK Kinase Inhibitor Overcomes Acquired Resistance to Prior TRK Kinase Inhibition in Patients with TRK Fusion–Positive Solid Tumors

Alexander Drilon, Ramamoorthy Nagasubramanian, James F. Blake et al. · Cancer Discovery · 2017 · 433 citations · Full text

Medicine, Oncology, Pharmacology +16

Consensus scoring for ligand/protein interactions

Robert D. Clark, Alexander Strizhev, Joseph M. Leonard et al. · Journal of Molecular Graphics and Modelling · 2002 · 407 citations

Life Sciences, Biochemistry, Bioinformatics +12

RET Solvent Front Mutations Mediate Acquired Resistance to Selective RET Inhibition in RET-Driven Malignancies

Benjamin Solomon, Lavinia Tan, Stephen Q. Wong et al. · Journal of Thoracic Oncology · 2020 · 284 citations · Full text

Medicine, Oncology, Pharmacology +17

1–5 of 54